quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:21:07·90d
ANALYSTRating
Relmada Therapeutics Inc. logo

Leerink Partners resumed coverage on Relmada Therapeutics with a new price target

RLMD· Relmada Therapeutics Inc.
Health Care
Original source

Companies

  • RLMD
    Relmada Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 24UpdatePiper Sandler$12.00
  • Jan 23UpdateLeerink Partners$8.00
  • Dec 22UpdateJefferies$69.00
  • Nov 19UpdateMizuho$10.00
  • Dec 5UpdateMizuho$1.00
  • Sep 17UpdateJefferies$13.00

Related

  • SEC6d
    SEC Form DEFA14A filed by Relmada Therapeutics Inc.
  • SEC6d
    SEC Form DEF 14A filed by Relmada Therapeutics Inc.
  • SEC14d
    SEC Form EFFECT filed by Relmada Therapeutics Inc.
  • SEC14d
    SEC Form 424B3 filed by Relmada Therapeutics Inc.
  • SEC17d
    SEC Form PRE 14A filed by Relmada Therapeutics Inc.
  • SEC20d
    SEC Form S-3 filed by Relmada Therapeutics Inc.
  • ANALYST31d
    Piper Sandler initiated coverage on Relmada Therapeutics with a new price target
  • SEC34d
    Relmada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022